Mary Caffrey

David O. Barbe, MD, MHA, president of the American Medical Association (AMA), made his remarks as private funders are stepping up support for research on gun violence.

The authors speculated that some cancer regimens, such as those with corticosteroids, cause hyperglycemia.

Researchers are examining combination therapies with immunotherapy, with and without chemotherapy.

FDA has fast-tracked the Biologics License Application for cemiplimab, with a decision expected October 28, 2018.

Regeneron's Matthew Fury, MD, said the decision to move immediately to a phase 3 trial came after 2 of 3 patients in a phase 1 trial showed durable responses.

Public health messaging has typically focused on the volume of walking not the intensity. This study suggests for those with limited time, a faster pace could make a difference.

The top status comes as digital providers, such as Omada Health, are trying to convince CMS to include them in the Medicare National Diabetes Prevention Program program.

The results support other evidence that suggests the link between irregular eating patterns and diabetes is distinctly different from the one that drives obesity.

Clinical trial data has shown that the drug helped 28.6% of patients achieve glycated hemoglobin of 7.0% of less by week 24 without severe hypoglycemia or diabetic ketoacidosis and also helped participants lose weight.

Data from the Mayo Clinic suggest that smokers who have quit longer than 15 years may need to be screened for lung cancer, yet they fall outside the window recommended by the United States Preventive Services Task Force.

Researchers based at the University of Michigan compared patients admitted to the intensive care unit (ICU) in Medicaid expansion states with those in nonexpansion states, focusing on 18 specific conditions identified as severe illnesses that could be avoided through better preventive care.

From smartphones to smart rescue inhalers, researchers offered ideas to make chronic obstructive pulmonary disease care more data-driven and personalized.

Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population.

Two scientists taking part in a session on addiction and pulmonary health outlined existing evidence about marijuana's effects on chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and cancer. But one speaker warned there are too few longitudinal studies in this area.

Results presented at the American Thoracic Society 2018 International Conference confirm a hypothesis about the connections among pollution, inflammation, and oxidative stress.

A session at the American Thoracic Society 2018 International Conference examined the factors that contribute to disparities and potential partnerships between doctors and lawyers on behalf of patients.

Harvard healthcare economist Michael E. Chernew, PhD, who is co-editor in chief of The American Journal of Managed Care®, discusses elements of the Trump administration proposal to control drug prices.

Officials with GlaxoSmithKline said COLUMBA is the first long-term study for an anti-IL5 biologic to treat severe asthma that has been reported.

Attendees at the American Thoracic Society 2018 International Conference, meeting in San Diego, California, heard details that led to FDA's recent expansion of the indication for GlaxoSmithKline's Trelegy Ellipta, including findings that the once-daily combination also provides significant mortality benefits over a dual therapy that is often the combination patients with chronic obstructive pulmonary disease (COPD) are taking when triple therapy is recommended.

The study comes as FDA is moving to bring more order to the area of mobile health. It is in the midst of a pilot for a precertifcation process that involves well-known companies such as Apple, Verily, and diabetes-specific companies like Tidepool.

Organizers of the project said it aims to build a better set of data on hypoglycemia that will help researchers and clinicians understand the condition, predict it, and gauge its cost.

The HHS secretary took on critics who said the plan went too easy on pharma and touted provisions that he said would change incentives that have worked in favor of companies and against patients.

Out-of-pocket costs for consumers and targeting the complex pharmaceutical rebating system were the high points of a presentation that began in the Rose Garden and ended with HHS Secretary Alex Azar's details in the White House press room.

In testimony before a Senate committee, the chief scientific and medical officer said no single stakeholder is at fault, but the entire system of insulin delivery must be examined to make things better for consumers.

FDA Commissioner Scott Gottlieb, MD, has embraced the calorie counts at restaurants a year after his agency put them hold on the eve of his arrival. A Nutrition Facts label update is delayed but not scuttled, in contrast with the reversal of school lunch changes from the Obama administration.

Authors report theirs is the first real-world study comparing the 2 SGLT2 inhibitors.

This week's announcement comes after cardiologists have spent several years sharing accounts of their difficulty gaining access to PCSK9 inhibitors for their patients.

CMS Administrator Seema Verma called on qualified providers of the National Diabetes Prevention Program to become Medicare suppliers. But in last year's rulemaking process, commenters warned that the program CMS had designed was too bureaucatic and did not pay enough upfront to attract small, community-based providers.

While precise pricing information was not released, net pricing will be within the cost-effective ranges set by the Institute for Clinical and Economic Review.

Even though her final stretch at the helm of Planned Parenthood was not easy, Cecile Richards told the nation's obstetricians she is optimistic because of the activism she sees among women and girls at the grassroots level. "Women are on fire," she said.